J.P. Morgan, in partnership with the Shanghai municipal government, will host its inaugural Global Healthcare Conference, Shanghai Forum, on October 12-13.
The flagship event of the International Biopharma Industry Week Shanghai 2021 brings together government officials, industry leaders, emerging companies, innovative technology creators and members of the investment community to discuss trending topics in the healthcare sector, including the outlook for the industry, rise of Chinese biotech firms, status of vaccine development, and new technologies and investment themes in this fast evolving space.
Mark Leung, CEO of J.P. Morgan China, said: “2021 marks the 100th anniversary of J.P. Morgan in China. We are committed to providing new and innovative offerings as China’s economy continues to grow, and investing to better serve our clients in rapidly developing sectors such as healthcare – a field where services and technology are making great advances.”
Shanghai is an important hub for the healthcare sector in China, with strong research and innovation capabilities. The city is home to more than 240,000 healthcare professionals, and 18 of the top 20 global pharmaceutical companies have their China headquarters or research centers located in Shanghai.
J.P. Morgan is a leading financial institution in the healthcare industry globally and the host of the world’s largest healthcare investment symposium – the J.P. Morgan Healthcare Conference, held in San Francisco every year. In 2021, over 8,000 participants attended to hear and learn from over 400 private and public companies that are defining the healthcare industry; next year marks the symposium’s 40th edition and will be held in January 2022.
Through the partnership with the Shanghai municipal government, J.P. Morgan combines its global strength and scale with localized expertise to make the Global Healthcare Conference, Shanghai Forum, a unique platform for the healthcare industry in China and globally.
Houston Huang, CEO and Head of Investment Banking, J.P. Morgan Securities (China) Company Limited, said: “With 30 percent of the global healthcare investments and financing taking place in China in 2020, and given the heightened awareness as a result of the pandemic, the country’s healthcare sector will continue to be a keen area of focus for the investment community. This sector has long been important to J.P. Morgan in China, and we will continue to strengthen our healthcare investment banking services – both onshore and offshore – to better support our clients and execute some of the market’s most important transactions.”
About JPMorgan Chase & Co.
JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $3.7 trillion and operations worldwide. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of customers in the United States and many of the world’s most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.
J.P. Morgan in China
J.P. Morgan has been doing business in China since 1921. J.P. Morgan’s integrated financial services include investment and corporate banking, wholesale payments, markets, sales and research, securities services, commercial banking and asset management. Today, the firm serves Chinese and international corporations, financial institutions and government agencies through our network across China.
J.P. Morgan Securities (China) Company Limited
Headquartered in Shanghai, J.P. Morgan Securities (China) Company Limited was founded in 2019. The firm provides a comprehensive set of financial products and services in China for its Chinese and international clients including securities brokerage, securities investment advisory, and securities underwriting and sponsorship.
In August 2021, J.P. Morgan announced that the China Securities Regulatory Commission has approved the registration of J.P. Morgan International Finance Limited taking 100% ownership of J.P. Morgan Securities (China) Company Limited, making it the first foreign firm to fully own a securities venture in China.